NI Research (NIR) has released the July/August issue of NeuroPerspective, which features a midyear overview of the neurotherapeutics area, and a comprehensive review of ALS.
The midyear overview provides capsule summaries and comments for 109 neurotherapeutics companies, as well as sections assessing Highlights and Lowlights from 1H:15. The flow of resources via funding and partnering activites is evaluated, with a particular eye to the potential emergence of a ‘bubble’ in neuroscience investment. There are extensive comments regarding developments at SAGE Therapeutics, Marinus Pharmaceuticals, Denali Therapeutics, and Axovant Sciences, amongst many. The most important anticipated clinical and developmental events for 2H:15 are explored in this thorough broadband scan of the neuro sector.
The second major component of this issue is a comprehensive review of ALS. ALS is an orphan neurodegenerative whose cruel impact upon patients and their families provide it with a sense of urgency far beyond its affected population size: the therapeutic options for ALS in 2015 are the same as they were twenty years ago. Misfolded protein clearance and neuroinflammation are among the more prominent mechanistic themes being pursued at present, while neurotrophic factors delivered via stem cells have produced high-profile but highly ambiguous results in pilot studies.
The July/August issue includes a Company Review of Marinus Pharmaceuticals, and a look back across the twenty years that NI Research has published NeuroPerspective/NeuroInvestment. Released as a 57 page pdf. This issue is being made available for single-issue purchase; $300.Read More